CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.316
NA - Nord America 5.095
AS - Asia 3.496
SA - Sud America 513
AF - Africa 58
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 14.490
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.964
RU - Federazione Russa 2.023
SG - Singapore 1.314
GB - Regno Unito 1.242
CN - Cina 1.209
BR - Brasile 432
IT - Italia 368
HK - Hong Kong 340
SE - Svezia 321
FR - Francia 306
IE - Irlanda 293
DE - Germania 264
VN - Vietnam 233
FI - Finlandia 232
KR - Corea 103
UA - Ucraina 76
CA - Canada 75
TR - Turchia 47
IN - India 45
JP - Giappone 40
MX - Messico 40
AR - Argentina 35
PL - Polonia 33
ID - Indonesia 32
NL - Olanda 30
BE - Belgio 29
ES - Italia 23
IR - Iran 23
BD - Bangladesh 22
ZA - Sudafrica 21
IQ - Iraq 16
AT - Austria 11
EC - Ecuador 11
PK - Pakistan 10
AE - Emirati Arabi Uniti 8
CH - Svizzera 7
LT - Lituania 7
MA - Marocco 7
PE - Perù 7
UY - Uruguay 7
VE - Venezuela 7
AZ - Azerbaigian 6
CL - Cile 6
UZ - Uzbekistan 6
AU - Australia 5
BY - Bielorussia 5
CO - Colombia 5
EG - Egitto 5
GR - Grecia 5
PH - Filippine 5
PT - Portogallo 5
AL - Albania 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
HR - Croazia 4
JO - Giordania 4
LV - Lettonia 4
PA - Panama 4
SA - Arabia Saudita 4
TW - Taiwan 4
BJ - Benin 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EU - Europa 3
HN - Honduras 3
KW - Kuwait 3
LU - Lussemburgo 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
ET - Etiopia 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MD - Moldavia 2
NO - Norvegia 2
OM - Oman 2
PY - Paraguay 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BT - Bhutan 1
BW - Botswana 1
CR - Costa Rica 1
GM - Gambi 1
GT - Guatemala 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
Totale 14.476
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Moscow 701
Chandler 644
Dallas 625
Jacksonville 563
Singapore 532
Woodbridge 408
Ashburn 362
Hong Kong 330
Dublin 290
Ann Arbor 281
Beijing 239
Houston 206
Verona 142
Lawrence 106
Princeton 106
Wilmington 100
New York 92
Jinan 91
The Dalles 83
Los Angeles 80
Nanjing 79
Ho Chi Minh City 67
Shenyang 65
Tianjin 61
Buffalo 56
Helsinki 56
Hebei 49
Changsha 42
Columbus 42
São Paulo 42
Munich 41
Sindelfingen 39
Santa Clara 37
Tokyo 37
Zhengzhou 37
Seoul 36
Dong Ket 35
Hanoi 33
Seattle 32
Milan 31
Boardman 29
Brussels 29
Redondo Beach 28
Guangzhou 27
Jakarta 26
Warsaw 26
Haikou 25
Ningbo 25
Hangzhou 24
Jiaxing 24
Redwood City 23
London 22
Montreal 22
Taizhou 22
San Francisco 21
Taiyuan 21
Turku 20
Nanchang 19
Stockholm 19
Denver 18
Norwalk 18
Brooklyn 17
Chennai 17
Johannesburg 17
Lancaster 17
Bologna 16
Fuzhou 16
Rio de Janeiro 15
Atlanta 14
Council Bluffs 14
Redmond 14
Chicago 13
Falkenstein 13
Montréal 13
Padova 13
Frankfurt am Main 12
Nuremberg 12
Poplar 12
Boston 11
Da Nang 11
Mexico City 10
Shanghai 10
Amsterdam 9
Biên Hòa 9
Brasília 9
Phoenix 9
Toronto 9
Vancouver 9
Belo Horizonte 8
Curitiba 8
Lappeenranta 8
Orem 8
Paris 8
Tehran 8
Ankara 7
Charlotte 7
Guayaquil 7
Ha Long 7
Kent 7
Totale 8.883
Salva come PNG Salva come JPEG
Nome #
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 243
Anti PSMA immunotoxins activity against prostate cancer cell lines. 238
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 205
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 205
Immunotoxins and other conjugates: preparation and general characteristics. 204
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 202
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 202
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 201
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 191
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 190
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 189
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 185
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 182
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 182
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 181
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 177
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 175
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 175
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 173
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 170
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 168
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 168
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 167
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 164
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 163
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 163
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 162
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 162
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 162
N-terminal deletion affetcs catalytic activity of saporin toxin. 158
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 157
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 154
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 152
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 152
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 152
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 150
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 149
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 149
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 148
Cloning and characterisation of canine prostate-specific membrane antigen 147
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 144
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 144
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 142
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 141
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 140
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 139
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 139
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 136
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 136
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 136
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 135
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 135
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 134
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 133
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 133
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 133
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 132
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 131
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 130
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 127
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 126
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 125
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 124
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 121
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 120
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 118
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 118
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 117
Effect of therapeutic macromolecules in spheroids 115
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 114
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 112
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 110
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 109
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 108
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 108
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 106
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 105
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 104
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 103
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 100
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 99
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 98
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 97
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 97
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 96
Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. 95
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 93
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 92
Ribosome-inactivating protein-containing conjugates for therapeutic use 92
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 91
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 91
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 90
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 89
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 87
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 87
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 86
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children 84
Targeting prostate cancer cells with D2B-gold Nanoparticles 83
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 83
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors 80
Totale 13.810
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.567
article - articoli 35.778
book - libri 0
conference - conferenze 11.184
curatela - curatele 0
other - altro 0
patent - brevetti 849
selected - selezionate 0
volume - volumi 756
Totale 97.134
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021423 0 0 0 0 0 101 21 66 52 20 97 66
2021/2022884 79 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/20252.436 113 153 61 367 169 82 123 112 403 186 223 444
2025/20264.529 506 447 618 1.103 1.808 47 0 0 0 0 0 0
Totale 14.607